Announcements Trials
Browse Landscape

Phase

Phase NA 51Phase 3 29Phase 2 28Phase 1 19Phase 1/2 12Phase 2/3 4Phase 4 2Phase EARLY_PHASE1 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 6Prostatic Neoplasms 4Neoplasms 4Lung Neoplasms 4Stomach Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Oropharyngeal Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Cholangiocarcinoma 3Breast Neoplasms 3Weight Loss 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Recurrence 2Myasthenia Gravis 2Mouth Neoplasms 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma 2Cachexia 2Anorexia 2

Interventions

Pemetrexed 3pembrolizumab 2Cisplatin 2Carboplatin 2dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Vitamin B 12 1Ramucirumab 1Paclitaxel 1Leucovorin 1Gemcitabine 1Folic Acid 1Docetaxel 1Dexamethasone 1Calcium Dobesilate 1ALT-803 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Lung Neoplasms × 30 days × Clear all
NCT07063745 2026-06-05

MountainTAP-29

Bristol-Myers Squibb

Phase 2/3 Recruiting
590 enrolled
Thoracic

Lung Neoplasms

NCT06851663 2026-05-29

Trop2-targeted immunoPET Imaging of Solid Tumors

RenJi Hospital

Phase 2/3 Recruiting
400 enrolled
GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07100080 2026-05-27

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Bristol-Myers Squibb

Phase 2/3 Recruiting
500 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡